Can the heart repair its own valve? a new surgical approach
NCT ID NCT07761273
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial tests a new surgical technique for people with tricuspid valve disease, where the valve on the right side of the heart is damaged. Instead of replacing the valve with an artificial one, surgeons will use a piece of the heart's own chamber, called the right atrial appendage, to rebuild it. The study will compare this approach to standard valve replacement, looking at safety, survival, and how well the new valve works over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Surgical procedure using the right atrial appendage to reconstruct the tricuspid valve
- What this could lead to
- If successful, this approach could offer a safer, more durable alternative to standard tricuspid valve replacement, potentially reducing complications and improving heart function.
- What could go wrong
- This is a small, early-stage trial, so results may not apply broadly. Surgery carries risks like bleeding, infection, or the new valve not working well, and long-term outcomes are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * all patient need tricuspid valve replacement Exclusion Criteria: * patient refusal
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tricuspid valve disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Amr El Sayed Tawfek
Zagazig, Sharqia Province, 44519, Egypt
-
Amr Tawfek
Zagazig, Sharqia Province, 44519, Egypt
-
cardiothorathic surgery department -faculty of medecine-zagazig univeristy- Egypt
Zagazig, Sharqia Province, 44519, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a catheter valve replace Open-Heart surgery for a leaky heart valve?
- New heart valve device aims to fix tricuspid leak without open surgery
- New heart valve device aims to fix tricuspid leak without open surgery
- New heart valve aims to improve tricuspid replacement outcomes
- Researchers track 400 patients with leaky heart valve to uncover prognosis
- New heart valve device aims to ease severe leak